A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
Condition: Coronary Artery Disease; Healthy Participants
MeSH terms: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Thrombosis
Intervention: Ticagrelor; BMS-986141; Aspirin
Intervention description: Specified dose on specified days; Specified dose on specified days; Specified dose on specified days
Intervention MeSH terms: Aspirin; Ticagrelor
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 58.0
Sex: All
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Thrombosis; Coronary Artery Disease; Healthy Participants; Aspirin; Ticagrelor; Brilinta; BMS-986141

Summary:

      The purpose of this study is to assess the effectiveness, safety and tolerability of
      BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both
      healthy participants and participants with stable coronary artery disease.
    

Eligibility criteria:

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit: www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male or female between 18 to 75 years of age, inclusive, and body mass index (weight
             kg/m2) between 18 and 35 kg/m2 (inclusive), and body weight 50 kg and 120 kg
             (inclusive)

          -  Judged to be generally in good health based on medical history, physical examination,
             ECGs, vital signs and laboratory tests

          -  Signed an informed consent document indicating they understand the purpose of and
             procedures required for the experiment and are willing to participate in the
             experiment

          -  Willing/able to adhere to the visit schedule

          -  For treatment arms groups with stable CAD participants (not for healthy volunteers
             without CAD) one or more of: Prior angiographically proven CAD (>50% stenosis of
             proximal coronary artery), prior coronary revascularization (PCI or CABG), prior
             myocardial infarction (MI)

        Exclusion Criteria:

          -  Participants who meet any of the following criteria will be excluded from
             participating in the experiment: Allergies or intolerance of aspirin, ticagrelor and
             BMS-986141, requirement for dual antiplatelet therapy, requirement for anticoagulant
             therapy

          -  Acute Coronary syndrome or coronary revascularization within 3 months

          -  Coagulation disorders (including any abnormal bleeding or blood dyscrasias), anemia,
             renal or hepatic insufficiency or any others illness that the investigator considers
             should exclude the participants/patients of that could interfere with the
             interpretation to the results

          -  Acute illness, including a common cold, within 7 days prior to visit or other
             significant acute or chronic medical illness

          -  Major or traumatic surgery within 12 weeks of screening

          -  History of, a reason to believe that, a blood donor subject has a history of drug or
             alcohol abuse within the past 5 years or has not abstained from alcohol for at least
             24 hours prior to visit

          -  Positive serum or urine pregnancy test

          -  Not anatomically suitable for or unwilling to undergo venipunctures

          -  Participation in a study of an investigational medicinal product within the last 4
             weeks

          -  Any condition that, in the opinion of the investigator, would compromise the wellbeing
             of the blood donor subject or the experiment or prevent the blood donor subject from
             meeting or performing experiment requirements

        Other protocol-defined inclusion/exclusion criteria apply